← Back to Home

Roche Expands Hansoh ADC Partnership With $400 Million Upfront Payment, Building a Preclinical Cancer Drug Portfolio

The collaboration expands from a single drug to multiple early-stage programs, with Hansoh advancing them through global Phase Ia trials before Roche takes over development outside Greater China. More than $15 billion in potential milestone payments remains contingent on development, approval and commercialization outcomes.

By SURL BioNews

Before the cancer drugs have entered human trials, a multinational pharmaceutical company has already committed funding and development resources. Hansoh Pharmaceutical announced on October 19 that it had expanded its antibody-drug conjugate (ADC) collaboration with Roche, with a $400 million upfront payment covering two preclinical drug candidates and multiple programs against new targets. This is the companies’ second ADC collaboration, expanding its scope from an individual product to a portfolio of early-stage research and development programs.

ADCs link an antibody that recognizes a specific marker to a cytotoxic drug, with the aim of delivering the drug to tumors. This collaboration covers two existing preclinical ADCs from Hansoh, as well as multiple programs using Hansoh’s technology platform to develop drugs against targets proposed by Roche. However, the companies have not disclosed the targets, specific cancer types or drug payloads for these programs, so it is not yet possible to assess how they differ from existing ADCs.

The payment structure also reflects the long development path ahead. In addition to the $400 million upfront payment, Hansoh will receive $110 million on the agreement’s first anniversary and could receive more than $15 billion in development, regulatory approval and commercialization milestone payments, along with tiered royalties on future sales. The substantial milestone figures are conditional on achieving specified goals and cannot be treated as guaranteed transaction revenue.

Development responsibilities will be transferred in stages: Hansoh will handle early research and development through completion of global Phase Ia clinical trials, after which Roche will undertake further development outside mainland China, Hong Kong, Macao and Taiwan. Hansoh retains development, registration and commercialization rights in those Greater China markets. Under this arrangement, Hansoh will continue to lead the candidates’ initial human safety and dose-finding studies.

Hansoh also retains an option to participate more extensively in overseas development. It may select up to two programs for participation in development outside Greater China, giving it an opportunity to receive additional returns from commercialization in the United States. The announcement did not explain how those returns would be calculated, so they cannot yet be translated into a specific profit-sharing percentage.

Roche told Reuters that the collaboration would complement its internal research and advance ADCs as one of the core elements of its next-generation oncology treatment strategy. Although funding and development responsibilities for this collaboration have been established, its clinical value remains to be demonstrated. No human efficacy or safety results have been made public, and there is no timetable for the first entry into clinical trials.

According to Hansoh’s announcement filed with the Hong Kong Stock Exchange, the agreement was signed on October 17, and closing remains subject to customary conditions, including expiration of the applicable waiting period under the U.S. Hart–Scott–Rodino Act and necessary regulatory filings. What will give this collaboration more substance next will be disclosure of the drug candidates’ identities, preclinical evidence and human trial plans, rather than the potential total payments themselves.

References

  1. Hansoh Pharmaceutical
  2. Hansoh Pharmaceutical Group / HKEX
  3. Reuters via MarketScreener
  4. BioPharm International